A Report Illuminating the Future: How Far Have We Come in the Fight Against Cancer?
In this article
Why Is This Report So Important?
Despite every advance in modern medicine, cancer remains one of the greatest threats to global public health and one of the most complex diseases . Following current cancer research therefore matters not only for us as medical oncologists developing treatment strategies, but also for society's understanding of promising scientific progress .
The American Association for Cancer Research (AACR) publishes the Cancer Progress Reportannually, comprehensively showing how scientific breakthroughs from July 2024 to June 2025 moved from the laboratory into clinical practice. The report documents achievements while also highlighting unresolved challenges such as rising early-onset cancers and inequalities in treatment access .
✅ Alongside treatments and screening methods that save millions of lives, the report provides a concrete roadmap for areas needing greater research investment.
In particular, it clearly documents how federal investment in research has saved millions of lives . The Cancer Progress Report is therefore more than a statistical document: it is also a forward-looking call for policy action .
More Than 4.5 Million Lives Saved: What Do the Statistics Show?
1991–2023 in the United States saw the overall cancer death rate fall by 34%. This decline means more than 4.5 million deaths avoided . The report states that, as of 2025, the United States has approximately 18.6 million cancer survivors —people diagnosed with cancer who are still living. Taken together, these findings show an established trend toward longer, fuller lives after a cancer diagnosis.
| Indicator | Value | What Does It Mean? |
|---|---|---|
| Change in overall death rate (1991–2023) | 34% reduction | Long-term decline through treatment, screening, and risk reduction |
| Deaths avoided (cumulative) | >4.5 million | Lives gained by delaying/preventing premature death |
| Cancer survivors (2025, United States) | ~18.6 million people | More people living longer, higher-quality lives after diagnosis |
📌 How is it measured? The "overall cancer death rate" is usually an age-adjusted measure, allowing trends to be compared without demographic effects such as population aging. "Deaths avoided" is the cumulative difference between deaths expected without the decline and those actually observed.
How Was This Achieved? Contributions From Multiple Factors
- Tobacco control: Lower smoking rates reduced mortality in many cancers, particularly lung cancer.
- Early detection: Mammography, colonoscopy, HPV-based cervical screening, and algorithm-assisted screening detect cancer at an earlier stage .
- New treatments: Targeted therapies, immunotherapies, and combination regimens improve survival.
- Supportive care: Advances in infection prophylaxis, nausea control, pain management, and nutrition improve treatment continuity .
⚠️ An important counterbalance: Despite these gains, rising early-onset cancers and access inequalities slow progress in some groups. Updated screening strategies, lifestyle interventions, and equity in healthcare access are therefore essential.
The underlying message is clear: Long-term, evidence-based investment in research funding, tobacco control, screening programs, and access to innovative treatment produces dramatic survival gains . Sustaining this trend requires determined, simultaneous support for preventive medicine and treatment innovation .
A New Era in Cancer Treatment: 20 New Medicines Approved
From July 2024 to June 2025, the FDA approved 20 new cancer medicinesand expanded the indications of 8 oncology agents to new cancer types .This pace shows that precision medicine is becoming routine and molecular targets are translating into clinical outcomes .
📊 Summary: Among the new approvals, ADCs particularly for lung cancer, IDH-targeted glioma treatment, a menin inhibitor (revumenib), and cellular immunotherapies (CAR-T / BiTE) stand out.
| Category | Clinical Contribution | Note |
|---|---|---|
| ADCs (Antibody-Drug Conjugates) | Selective delivery of chemotherapy to tumors: efficacy ↑, systemic toxicity ↓ | For lung cancer, 2 new approvals; target-antigen selection is crucial |
| IDH-targeted glioma treatment | In young adults with diffuse glioma, the potential to DELAY PROGRESSION . | In glioma, the first IDH1/2-targeted approval; important for long-term planning |
| Menin inhibitor (revumenib) | In KMT2A-rearranged / NPM1-mutant AML, a chance of deep responses . | Risk of differentiation syndrome; close monitoring required |
| Cellular immunotherapies (CAR-T / BiTE) | In refractory hematologic malignancies, high response rates | CRS/ICANS management and access/cost are major limitations |
Antibody-Drug Conjugates (ADCs): Greater Efficacy Through Selectivity
ADCs use a monoclonal antibody binding to a target antigen, with a linker carrying a cytotoxic payload, which is released directly into the tumor cell . This increases tumor-selective effects while relatively reducing systemic toxicity.
- Clinical result: In previously treated lung cancer, potential improvements in response rates and PFS .
- Practical tip: Antigen expression level is critical to patient selection; biomarker testing is essential.
- Safety: Interstitial lung disease / pneumonitis and ophthalmic toxicities require early warning and proactive management .
IDH-Targeted Treatment in Brain Tumors: A First in Glioma
Approved for IDH1/2-mutant diffuse glioma, the first targeted treatmentsuppresses tumor metabolism (2-HG accumulation) to slow tumor evolution . Particularly for young adults, it enables treatment planning aligned with long-term functional living goals.
🧭 Guideline implications: IDH testing is no longer merely a diagnostic note; it determines treatment decisions as a central biomarker.
A Revolution in Hematology: Menin Inhibitors and Cellular Therapies
Revumenib and similar menin inhibitors target the menin-KMT2A axis in KMT2A-rearranged or NPM1-mutant AML, showing potential for deep, durable responses . Meanwhile, CAR-T and BiTE approaches can produce meaningful responses even in refractory cases.
- Adverse-effect management: Menin inhibitors: differentiation syndrome; CAR-T/BiTE: CRS, ICANS require early warning protocols and center expertise.
- Access and cost: Manufacturing/logistics, inpatient monitoring, and supportive care needs make equitable access planning essential.
8 Indication Expansions: The Right Treatment for the Right Patient
Extending some agents to new tumor types or early-stage/adjuvant settings enables early, personalized intervention in treatment algorithms. These expansions improve quality and standards in biomarker-based patient selection.
- Tumor-agnostic trend: Certain molecular targets are moving toward organ-independent approvals.
- Early-stage impact: In minimal residual disease, the chance to reduce recurrence risk .
Impact on Clinical Practice: What Has Changed?
- Biomarkers are essential: Using ADCs and targeted agents requires tissue/blood-based testing .
- The side-effect ecosystem: ADC-associated pneumonitis, menin inhibitor-associated differentiation syndrome, and CAR-T/BiTE-associated CRS/ICANS require multidisciplinary management .
- An early integrated approach: Expanded indications mean that, for early-stage patients too, a chance of cure / long-term control is an increasingly prominent goal.
Breakthroughs Turning the Immune System into a Cancer Hunter
Immunotherapies, particularly immune checkpoint inhibitors (ICIs) and cellular therapies (CAR-T, BiTE), changed the paradigm of cancer treatment. In 2011, ICIs were approved for only 1 cancer type; by 2025, they were standard options in more than 20 tumor types. This expansion marks an era of treatment capable of providing long-lasting responses and durable disease control .
Immune Checkpoint Inhibitors (ICIs): Releasing the Brakes
ICIs targeting the PD-1/PD-L1 and CTLA-4 pathways release the “brakes” on T cells, reactivating antitumor immunity . Selected patients may experience long-lasting complete/partial responses and a plateau effect on survival curves.
Biomarkers: How Do We Select the Right Patient?
- PD-L1 expression: Associated with the likelihood of response; the threshold and testing platform matter.
- MSI-H/dMMR: Opened the door to tumor-agnostic approvals; high neoantigen burden → strong responses.
- TMB (Tumor Mutational Burden): May predict potential benefit in some tumors; methodology and cut-off are critical.
- Viral antigens / immune microsignature: The immune system can be targeted in specific settings, such as HPV-associated tumors.
| Dimension | Clinical Significance | Note |
|---|---|---|
| Single-agent ICI | Better tolerated; potential for a durable response with an appropriate biomarker | Markers such as high PD-L1 expression and MSI-H support selection |
| Combination ICI (PD-1+CTLA-4) | Response and depth ↑ | Risk of immune-related toxicity ↑; an experienced center is essential |
| Chemotherapy/antiangiogenic therapy + ICI | May increase response by making the microenvironment “hot” | Now part of standard regimens in selected solid tumors |
Cellular Immunotherapies: CAR-T and BiTE
CAR-T cellsare produced by genetically reprogramming the patient's T cells to recognize a tumor antigen; following infusion, in vivo clonal expansion can produce a powerful cytotoxic effect. BiTE antibodies simultaneously bind a T cell and a tumor cell, creating an immune synapse and initiating a killing response.
- Range of indications: High response rates, particularly in refractory/relapsed hematologic malignancies.
- Logistics: Requires apheresis, manufacturing, bridging therapy, and intensive monitoring.
- Toxicity management: Early recognition and intervention protocols for CRS and ICANS (e.g., tocilizumab, steroids) are critical.
🧭 Clinical tip: Barriers such as antigen loss/escape, tumor microenvironment suppression, and manufacturing delays make planning combination strategies and early referral important.
Safety and Monitoring: Immune-Related Adverse Events (irAEs) and Management
- Common irAEs: Skin rash, colitis/diarrhea, hepatitis, pneumonitis, thyroiditis/hypothyroidism, and hypophysitis.
- Grading: Grading according to CTCAE; grade ≥2 toxicities often require treatment interruption and short- to medium-term steroids .
- Risk of late onset: irAEs can occur even months after treatment ends → long-term monitoring.
- A multidisciplinary approach: Close collaboration with pulmonology, gastroenterology, endocrinology, dermatology, and neurology.
A Quick Roadmap for Clinical Practice
- Plan biomarkers early: PD-L1, MSI-H/dMMR, TMB, and driver mutations.
- Choose a strategy based on the target: Single-agent ICI vs. combination; chemotherapy/anti-VEGF + ICI options in solid tumors.
- Provide toxicity education from the start: Explain warning signs of irAEs/CRS/ICANS to patients and families.
- Logistics and access: Arrange an appropriate center and timing for CAR-T/BiTE early.
- Update using real-world data: Update the algorithm as guidelines and insurance/reimbursement conditions change.
Artificial Intelligence and Minimally Invasive Tests in Early Diagnosis
Early diagnosis is the step with the greatest impact on treatment success and survival . Over the past year, artificial intelligence (AI)-assisted devices/software and blood-based and stool DNA-based screening tests, along with at-home sample collection solutions, received approval, marking a turning point that improves access and patient acceptance.
Artificial Intelligence (AI)-Assisted Diagnostic Tools
- Colonoscopy and endoscopy support: Provides real-time alerts for polyp/lesion detection, aiming to reduce the likelihood of missed lesions .
- Imaging analysis: On mammography, CT, and MRI, prioritization of suspicious findings and acceleration of workflow.
- Triage and workload management: In radiology and pathology, prioritization to shorten reporting times.
🧪 Clinical note: AI outputs provide decision support; final interpretation rests with the specialist physician . Performance is sensitive to the training data and deployment quality.
Minimally Invasive Screening for Colorectal Cancer
Blood-based liquid biopsy and next-generation stool DNA tests offer practical options that may increase screening participation. These tests reduce adherence/access barriers but do not replace colonoscopy; a positive result requires a confirmatory colonoscopy .
| Method | Advantage | Disadvantage / Note |
|---|---|---|
| Blood-based test | Easy sampling; high adherence | Colonoscopy required if positive; advanced adenoma detection performance varies |
| Stool DNA test | At-home sampling; noninvasive | Requires logistics/delivery tracking; if positive, colonoscopy is mandatory |
- Target population: Average-risk individuals who do not attend standard colonoscopy or postpone it.
- Intervals: Test intervals vary by product and risk; adherence to local guidelines matters.
At-Home Cervical Screening: An Innovation Lowering the Barrier
Approval of at-home sample collection devices has the potential to reduce privacy, time, and transportation barriers that lower screening participation. Samples are sent for HPV-based testing; positive results require colposcopy/additional testing .
📌 Practical tip: For sample collection, full adherence to instructions and traceable logistics (labeling, shipping) are critical to result quality.
A Quick Roadmap for Clinical Practice
- Stratify risk: Average vs. high risk (family history, genetics, IBD, etc.).
- Choose an appropriate method: Colonoscopy is the gold standard; for nonparticipants, consider blood/stool DNA tests.
- No delay after a positive result: Confirmatory colonoscopy should be scheduled as soon as possible.
- Use AI responsibly: In-house validation, quality metrics, and a regular feedback loop.
- Education and access: Clear instructions, reminders, and follow-up systems for at-home sampling.
Critical Challenges Persisting Despite Progress
Although survival gains are substantial, rising early-onset cancer rates, the high proportion of preventable risk factors and inequalities in care limit the pace of progress and its reach across all groups.
1) Rising Early-Onset Cancer Rates
Colorectal cancer (≤50 years): Incidence is increasing annually by ~5.0%.
→ Screening strategies require an earlier start and risk-based approaches.
Lifestyle and environmental factors: Obesity, sedentary living, dietary patterns, and changes in the microbiota may contribute.
→ Primary prevention and early symptom awareness are critical.
🧭 Clinical/practical recommendation: For people aged 40–45 with symptoms or a family history, a low threshold for evaluation (stool DNA/blood-based testing, colonoscopy in appropriate candidates) and short appointment intervals.
2) The High Proportion of Preventable Risk Factors
In the US, ~40% of cancers are attributed to modifiable risks:
- Tobacco: A major determinant of lung and upper aerodigestive cancers; smoke-free policies and cessation programs are essential.
- Overweight/obesity and physical inactivity: Increased risk of breast (postmenopausal), colorectal, endometrial, and other cancers.
- Alcohol: Dose-dependent risk; even “moderate” consumption alone adds to the risk of some cancers.
- Diet quality: Insufficient fiber, consumption of processed meat and sugary drinks, and inadequate protective nutrients.
- Infections and vaccination: Increasing HPV and HBV vaccine coverage and eradicating H. pylori.
| Intervention | Expected effect | Note |
|---|---|---|
| Tobacco cessation + taxation | Smoking prevalence ↓, lung cancer mortality ↓ | Benefits in both the short and long term |
| HPV/HBV vaccination programs | Significant reduction in cervical, head and neck, and HCC risk | Coverage and booster doses are critical |
| Diet/activity interventions | Multiple benefits, particularly for colorectal and breast cancer | Community/workplace-based programs are effective |
3) Inequalities: Differences in Access, Quality, and Outcomes
Among racial/ethnic groups and in areas with low socioeconomic status, screening, treatment access, and clinical trial participation rates are lower, leading to delayed diagnosis and poorer outcomes .
- Geographic barriers: Distance to oncology centers in rural areas; need for referral and accommodation support.
- Insurance/reimbursement: High out-of-pocket costs; limited access to innovative treatments and molecular tests.
- Cultural/language barriers: Can be overcome through navigation and health literacy programs.
📌 A policy-focused solution: Screening reminder systems, mobile screening units, broad reimbursement for molecular testing , and equitable representation in clinical trials.
What Can We Do Today? (Clinical Practice, Community, and Policy)
- Review screening thresholds: When early-onset disease is suspected, risk-based, flexible screening.
- Access to molecular testing: For biomarker-based therapies, early, widespread testing.
- Primary prevention packages: Tobacco cessation, diet and activity, alcohol reduction, and vaccination programs.
- Equitable logistics: Transportation/accommodation support, interpreter services, and patient navigation.
- Data-driven quality: Monitor and improve time delays, screening participation, and treatment initiation metrics.
Conclusion and a Call for Policy Action
The 15th Cancer Progress Report, with a 34% decline in mortality between 1991–2023 and >4.5 million deaths avoided , shows that evidence-based investment translates into tangible gains in lives saved . As of 2025, ~18.6 million survivors provide powerful evidence of how screening, risk reduction, and innovative treatments can work together to make a population-level impact.
📌 Strategic implication: Rising early-onset cancer rates and inequalities in care mean that gains need to be extended more widely and accelerated .
In summary: This report is both a success story and an ongoing call to action. When science, funding, and equitable implementation come together, earlier diagnosis, more effective treatment and longer lives of better quality can become the standard in cancer care.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.